Independent Advisor Alliance Trims Stake in AbbVie Inc. $ABBV

Independent Advisor Alliance lowered its position in AbbVie Inc. (NYSE:ABBV) by 3.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 112,718 shares of the company’s stock after selling 4,153 shares during the quarter. AbbVie comprises about 0.6% of Independent Advisor Alliance’s portfolio, making the stock its 22nd largest position. Independent Advisor Alliance’s holdings in AbbVie were worth $25,755,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of AbbVie by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after acquiring an additional 3,032,438 shares during the period. Legal & General Group Plc raised its stake in shares of AbbVie by 4.3% in the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after acquiring an additional 493,420 shares during the period. Wellington Management Group LLP raised its stake in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the period. Amundi raised its stake in shares of AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in shares of AbbVie by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after acquiring an additional 408,426 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $207.83 on Wednesday. AbbVie Inc. has a 1 year low of $176.57 and a 1 year high of $244.81. The firm’s 50-day moving average is $211.75 and its two-hundred day moving average is $220.44. The stock has a market cap of $367.20 billion, a price-to-earnings ratio of 102.38, a PEG ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the business earned $2.46 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. On average, equities analysts expect that AbbVie Inc. will post 14.32 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 340.89%.

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by corporate insiders.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Evercore ISI recently raised its price target on AbbVie to $236 from $232 and kept an Outperform rating, reinforcing the bullish analyst tone around the shares. Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
• Positive Sentiment: AbbVie’s full-year 2026 adjusted EPS guidance of $14.37 to $14.57 appears to be supporting confidence that earnings can remain durable even as the company transitions beyond Humira. AbbVie rises 3.3% as upbeat 2026 outlook and fresh analyst optimism lift sentiment
• Positive Sentiment: Recent articles highlighting strong long-term growth potential, rising dividends, and improving drug portfolio sentiment are helping position ABBV as a defensive healthcare name with income appeal. 3 Reasons to Buy AbbVie Stock (ABBV) Like There’s No Tomorrow
• Neutral Sentiment: At the 2026 Annual Meeting, shareholders elected directors and maintained AbbVie’s governance structure; this is supportive of continuity, but not likely a major stock-moving catalyst on its own. AbbVie Shareholders Back Directors, Maintain Governance Structure
• Neutral Sentiment: Several recent writeups argue that AbbVie’s growth engine is “firing on all cylinders,” largely due to SKYRIZI and RINVOQ, but these are more confirmation of the current narrative than a fresh catalyst. AbbVie’s Growth Engine Is Firing On All Cylinders
• Negative Sentiment: Some commentary remains cautious, noting that AbbVie has lagged the broader market over the past year and still faces pressure from competition and investor skepticism around its longer-term multiple. AbbVie Stock: Is Wall Street Bullish or Bearish?
• Negative Sentiment: News that a smaller biotech beat one of AbbVie’s major drug programs is a reminder that competitive risks remain in key therapeutic areas. A Tiny Biotech Just Beat AbbVie’s $17 Billion Drug. Should Investors Be Worried?

Analyst Ratings Changes

Several research analysts recently commented on ABBV shares. Canaccord Genuity Group raised their price target on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Citigroup reduced their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 price target on shares of AbbVie in a research note on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $252.90.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.